News Archive

What you get

Participants selected for cohort three will receive: *

• A two-year fellowship – Includes a personal living stipend of up to $90,000/year depending on education and experience, along with health insurance and travel allowance
• Lab access and research funding – In addition to unparalleled access to facilities, equipment, and expertise at Oak Ridge National Laboratory, fellows receive $200,000 of R&D funding to support collaboration opportunities with researchers across the lab.
• Business mentors, entrepreneurial training, and networking – Participants receive access to experienced business mentors, entrepreneurial training programs, and exclusive networking opportunities. Innovators are also exposed to a wide range of leaders from academia, industry, government, and finance that can serve as advisors and partners.

*All support is subject to performance and availability of funds.

Eligibility criteria

For acceptance into the program, applicants:

• Must have PhD or equivalent experience
• Must be focused on energy or manufacturing innovation
• Must leverage ORNL R&D capabilities and have an impact on the Department of Energy (DOE) or Tennessee Valley Authority (TVA) mission
• Must be willing to relocate to the Knoxville-Oak Ridge area
• Must be a US citizen or lawful permanent resident at time of application

To learn more or to apply, please visit: https://innovationcrossroads.ornl.gov/.

World-leading innovation

Discovery crosses industries, border and boundaries in MoCo

After a pair of key milestones this year, a startup working on a new way to treat cancer is opening an office in Baltimore city.

ImmuCision BioTherapeutics is taking office and lab space in the space at the University of Maryland BioPark at 801 Baltimore St.

Class has just begun, but U.S. News & World Report has already issued its report card for the nation’s best colleges.

And some familiar local names are up near the head of the class.

The Frederick Innovative Technology Center Inc., a technology incubator in Frederick, received the most money in fiscal year 2019 grant awards from the Rural Maryland Council’s Rural Maryland Prosperity Investment Fund.

A company started by former executives from Kite Pharma has raised $120 million to develop the next generation of CAR-T therapies.

A critical stage for most first-time entrepreneurs is getting their idea developed into at least a prototype to validate their technology. This process costs money, which professional investors are not willing to contribute, since their interest is in scaling a proven product and business model into a growth business. Investors want potential for a large and timely return, with reduced risk.

Register now for our 6th Annual Pediatric Device Innovation Symposium on Sunday, Sept. 23, in Philadelphia– one day before The MedTech Conference powered by AdvaMed as we co-locate again this year.

Join the conversation as our experts dive deep into the topic “Using Real World Evidence to Drive Pediatric Innovation”

Program highlights include a live podcast of “BioTalk with Rich Bendis” featuring Vasum Peiris, MD, Chief Medical Officer for Pediatrics and Special Populations, Food & Drug Administration.

SERAXIS Inc., a privately held regenerative medicine company today announced the successful production of stem cell derived pancreatic cells capable of regulating blood glucose in rodent models of insulin dependent diabetes.